Further, Her2 + and triple-negative patients had a higher expression of FBLN2 compared to LumA and LumB at lesions of invasive ductal carcinoma (IDC), ductal carcinoma in situ (DCIS), and control regions (Supplementary Fig. 7). Here, FBLN2 is linked to ductal breast carcinoma in situ.